Brief: EMA Says Tepezza Received Positive CHMP Opinion For Treatment Of Adults With Moderate To Severe Thyroid Eye Disease

Jazz Pharmaceuticals

25/04/2025 15:14

April 25 (Reuters) - EMA:

EMA SAYS CHMP WILL RE-EXAMINE OPINION ADOPTED FOR MARKETING AUTHORISATION HOLDER FOR KISUNLA (DONANEMAB)

EMA SAYS CHMP RECOMMENDS CONDITIONAL MARKETING AUTHORISATION FOR DUVYZAT (GIVINOSTAT), AS TREATMENT FOR DMD IN PATIENTS FROM AGE SIX WHO CAN WALK

EMA SAYS TEPEZZA (TEPROTUMUMAB) RECEIVED POSITIVE OPINION FROM CHMP FOR TREATMENT OF ADULTS WITH MODERATE TO SEVERE THYROID EYE DISEASE

EMA SAYS SEPHIENCE (SEPIAPTERIN) GOT POSITIVE OPINION FROM CHMP FOR TREATMENT OF HYPERPHENYLALANINAEMIA IN ADULTS & CHILDREN WITH PHENYLKETONURIA

EMA SAYS CHMP RECOMMENDED GRANTING CONDITIONAL MARKETING AUTHORISATION FOR ZIIHERA (ZANIDATAMAB)

Source text: [ID:]

Further company coverage: LLY.N

 ((Reuters.Briefs@thomsonreuters.com;))